TY - JOUR T1 - Radiation Therapy for Extrapelvic Lymph Node Recurrence After Curative Treatment for Cervical Cancer JF - Anticancer Research JO - Anticancer Res SP - 891 LP - 895 DO - 10.21873/anticanres.13190 VL - 39 IS - 2 AU - TAKASHI UNO AU - AKI KANAZAWA AU - MIHO WATANABE NEMOTO AU - RINTARO HARADA AU - HIROKI KOBAYASHI AU - MAKOTO SAITO AU - YUMA IWAI AU - HIROKAZU USUI AU - AKIRA MITSUHASHI AU - MAKIO SHOZU Y1 - 2019/02/01 UR - http://ar.iiarjournals.org/content/39/2/891.abstract N2 - Background/Aim: To investigate outcomes of patients with cervical cancer who received radiation therapy for extrapelvic lymph node recurrence after initial pelvic radiotherapy. Patients and Methods: The treatment charts of 20 patients were retrospectively reviewed, and factors influencing patient's prognosis were statistically analyzed. Results: The three-year in-field tumor control rate was 55% and overall survival (OS) at 2, 3, and 5 years was 55%, 45%, and 37.5%, respectively. The rate of the three-year OS in patients with recurrence within and after 9 months was 20% and 70%, respectively (p=0.016). None of the 4 patients who were diagnosed with supraclavicular lymph node recurrence alone at more than 9 months after initial treatment experienced further recurrence. Five-year survival of the remaining 16 patients was only 21% (p=0.021). Conclusion: Time to recurrence significantly influenced survival in patients with cervical cancer who received radiotherapy for extra-pelvic lymph node recurrence. Supraclavicular lymph node recurrence alone had a favorable impact on patient's prognosis. ER -